Metformin Mimics Exercise in Prostate Cancer

Researchers at the Miller School of Medicine's Sylvester Comprehensive Cancer Center have discovered that Metformin, a common diabetes drug, can replicate the metabolic benefits of exercise in men undergoing prostate cancer treatment. The study, published in EMBO Molecular Medicine, found that Metformin increases levels of N-Lactoyl-phenylalanine (Lac-Phe), a molecule associated with energy balance and weight regulation, even in inactive patients. This effect helps counter metabolic stress caused by hormone therapy, which often limits physical activity due to fatigue. While Metformin does not directly treat cancer, it supports overall metabolic health, improving patient tolerance to treatment and quality of life. Key researchers Marijo Bilić, Priyamvada Natarajan, and David B. Lombard emphasized the importance of this finding for patient care.